[
    [
        {
            "time": "2023-10-01",
            "original_text": "Diverse Large-Cap Stocks to Buy Now to Boost Your Long-Term Portfolio",
            "features": {
                "keywords": [
                    "Large-Cap",
                    "Buy",
                    "Long-Term",
                    "Portfolio"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Diverse Large-Cap Stocks to Buy Now to Boost Your Long-Term Portfolio",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "How Neurocrine Biosciences Crushed It in Q2",
            "features": {
                "keywords": [
                    "Neurocrine",
                    "Biosciences",
                    "Crushed",
                    "Q2"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "How Neurocrine Biosciences Crushed It in Q2",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]